What Vivita Technologies does

ViVita Technologies, Inc. is a privately held regenerative medicine company headquartered in Woodland, California, that develops xenogeneic extracellular matrix (ECM) biomaterials intended to address the shortage of donor organs and tissues. The company's core platform is the patented SPEAR Process (Stepwise Progressive Extracellular Matrix Antigen Removal), a protein chemistry method that uses stepwise, differential solubilization to eliminate up to 97% of detectable antigens from animal-derived tissues (including pericardium, artery, vein, and whole heart) while preserving native ECM structure and function. The resulting product, the BARE Patch, is an immune-compatible acellular ECM scaffold designed to be recognized as "self" by the recipient, enabling constructive pro-regenerative cellular repopulation and matrix remodeling in vivo.

The company's commercial focus is cardiovascular and heart valve replacement, targeting an annual U.S. market of approximately 100,000 procedures representing a $1.7 billion healthcare burden per American Heart Association data. BARE Patch is positioned as an off-the-shelf tissue and organ replacement intended to avoid long-term immunosuppressive medication and repeat transplants. As of the available data, ViVita is pre-revenue, with the BARE Patch in preclinical and FDA regulatory pathway development funded in part by a $1.5 million NIH Phase II grant awarded in September 2022. Revenue mechanics are not yet established; the company's stated intent is to commercialize a spectrum of ECM-based tissue and organ replacement products derived from the SPEAR Platform once regulatory milestones are achieved.

ViVita was co-founded by Maelene L. Wong, PhD (CEO) and Leigh G. Griffiths, VetMB, PhD (Chairman), both affiliated with UC Davis, and operates with a small team of 1-10 employees. The company has not disclosed venture financing beyond NIH non-dilutive grant funding and has not yet defined a pricing model, go-to-market channel strategy, or commercial customer base. A note on founding date: the firmographic record lists 2012 while legal/corporate documentation indicates a 2018 incorporation date, suggesting either an organizational predecessor or a data discrepancy that would warrant diligence.

Name

Vivita Technologies

Legal name

ViVita Technologies, Inc.

Website

https://vivitatechnologies.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

ViVita Technologies develops xenogeneic extracellular matrix biomaterials using its patented SPEAR antigen-removal process, targeting immune-compatible off-the-shelf cardiovascular and heart valve replacement products to address the donor organ shortage.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Biomaterials

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Acellular/Decellularized Matrices & ECM Products (HLAAAGAF)

akta.pro secondary industries

Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis) (HLAAAGAJ), Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)

Keywords

• Regenerative medicine biomaterials
• Xenogeneic tissue scaffolds
• Cardiovascular tissue engineering
• Acellular extracellular matrix
• Heart valve replacement

Headquarters

HQ city

Woodland

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure

Revenue model

1. Tissue and Organ Replacement Products: Pre-revenue company developing off-the-shelf xenogeneic extracellular matrix-based tissue and organ replacement products. Revenue model not yet established as products are in development for FDA approval.

Core offering

ViVita Technologies develops and manufactures immune-compatible regenerative biomaterials using its patented SPEAR Platform technology, which removes up to 97% of antigens from animal-derived tissues while preserving native extracellular matrix structure-function properties. Its flagship product, the BARE Patch, is an off-the-shelf acellular xenogeneic ECM scaffold designed for cardiovascular and heart valve applications, enabling tissue replacement that becomes the patient's own tissue following implantation.

Product overview

ViVita Technologies offers a unified platform architecture centered on two core products: the SPEAR Platform as the underlying technology engine and the BARE Patch™ as the resulting biomaterial product. The SPEAR Platform uses patented stepwise differential solubilization chemistry to remove immunological barriers from animal-derived tissues, generating acellular ECM scaffolds. The BARE Patch™ is the commercial application of this technology—an immune-compatible regenerative biomaterial that serves as a blueprint for tissue regeneration and becomes the patient's own tissue following implantation. Together, these products enable off-the-shelf tissue and organ replacements targeting cardiovascular applications, particularly heart valve replacement.

Differentiator

Problem solved

Functional benefit

Products and services

• BARE Patch An immune-compatible biomaterial derived from animal-derived tissues that removes immunological barriers while providing the body a blueprint for regeneration. The patch is designed for cardiovascular and heart valve applications, enabling off-the-shelf tissue replacement that becomes the patient's own tissue following implantation.
• SPEAR Platform A patented platform technology that employs protein chemistry principles of stepwise, differential solubilization to achieve antigen elimination in generating acellular xenogeneic ECM scaffolds. The process removes immunological barriers from animal-derived tissues, eliminating up to 97% of all detectable antigens while preserving native ECM structure-function properties.

Quantifiable outcome

• 97% antigen elimination from animal-derived tissues
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Humacyte: Humacyte develops bioengineered, acellular tissue vessels (e.g., HAV) using a regenerative platform analogous to ViVita's SPEAR-based acellular ECM scaffolds. Both are regenerative medicine companies commercializing off-the-shelf animal/human-cell-derived biologic conduits for vascular and cardiovascular applications.
• CorMatrix Cardiovascular: CorMatrix develops acellular extracellular matrix (ECM) products derived from porcine small intestinal submucosa for cardiac and vascular repair, directly competing with ViVita's BARE Patch in cardiovascular applications using xenogeneic ECM technology.
• MiMedx: MiMedx is a regenerative medicine company commercializing dehydrated human amnion/chorion membrane allografts and other tissue-based biologics for wound care and surgical applications, a directly comparable tissue-based biomaterial platform with similar regulatory and clinical dynamics.
• Organogenesis: Organogenesis commercializes regenerative wound care and surgical biologics (e.g., Apligraf, Dermagraft), making it a close direct peer to ViVita in the regenerative tissue/biologic scaffold category with similar FDA pathway and customer base dynamics.
• LeMaitre Vascular: LeMaitre Vascular manufactures biologic and synthetic vascular grafts (including xenogeneic/carotid shunt and cryopreserved tissue products) for cardiovascular and peripheral vascular surgery, directly comparable to ViVita's xenogeneic ECM vascular tissue direction.

Broad incumbents

• Integra LifeSciences: Integra LifeSciences is a larger, established medical device company with a broad regenerative technologies portfolio (e.g., Integra Dermal Regeneration Template) serving neurosurgery, wound care, and reconstructive surgery. It is a broad incumbent in regenerative ECM/scaffold products against ViVita's niche cardiovascular focus.
• Edwards Lifesciences: Edwards Lifesciences is the leading heart valve replacement company (surgical and transcatheter aortic, mitral, pulmonic valves) and represents the incumbent competitor in ViVita's initial cardiovascular application, with broad portfolio rather than a regenerative focus.
• Medtronic (Cardiac & Vascular): Medtronic is a broad incumbent in cardiovascular devices including surgical and transcatheter heart valves (CoreValve/Evolut) and tissue heart valves, representing the dominant competitor ViVita would need to displace in the heart valve replacement market.
• Abbott (Cardiovascular): Abbott's cardiovascular division (formerly St. Jude) manufactures mechanical and bioprosthetic heart valves (e.g., Trifecta, Regent, Tendyne) and structural heart devices. As a broad incumbent, it is a relevant peer for any company targeting the heart valve replacement market.
• Cook Medical (Surgical & Vascular): Cook Medical supplies a range of vascular grafts and bioprosthetic heart valves used in cardiac surgery. As a diversified incumbent in cardiovascular surgery products, it is a comparable peer for a regenerative xenogeneic tissue patch company entering the cardiovascular space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/ViVitaTech

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vivita Technologies